News
Follow us for the latest news

JHM BIOPHARMA has initiated the Phase III trial for recombinant botulinum neurotoxin of type A in treating upper limb spasticity in adults, with enrollment of the first patient completed.

Today, JHM Biopharmaceutical (Hangzhou) Co., Ltd. (here…

Learn More

JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity

JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM&…

Learn More

JHM Biopharmaceutical Raises Nearly CN¥350 million in Series B and B+ Financing

JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM&…

Learn More

JHM Biopharmaceutical Receives Approval for Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke Spasticity

JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM&…

Learn More

JHM Biopharmaceutical Achieves Over 20-Ton Production Capacity for Recombinant Human Collagen

JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM&…

Learn More